Filing Flows

Filing Flows › Companies › Kiniksa Pharmaceuticals International › Cash flow

Kiniksa Pharmaceuticals International cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$47.4M in Q3 2026 · $197M over twelve months

Operating cash flow$47.5M
Capital spending−$180K
Free cash flow+$47.4M
Cash / net income1.0×
Cash conversion cycle278 days

Analysis

In Q3 2026, Kiniksa Pharmaceuticals International generated $47.5M of operating cash flow and spent $180K on capital projects, leaving free cash flow of $47.4M. That is $14.4M more than in Q3 2025 ($33.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was $199M; the largest uses were other investing ($313M), taxes on employees’ shares ($15.8M), capital spending ($1.6M); besides operations, cash came from shares issued ($38.6M); the cash balance fell by $93.2M.

Operating cash flow was $47.5M against net income of $47.3M — 1.0× profit, roughly in line with earnings. The largest differences: inventory −$37.1M, accrued liabilities +$28.9M, stock-based pay +$13.1M.

Its cash conversion cycle was 278 days (receivables 9 + inventory 297 − payables 27).

Free cash flow

Kiniksa Pharmaceuticals International: free cash flow by quarterKiniksa Pharmaceuticals International: free cash flow by quarter$18.6MQ4 2024$22.2MQ1 2025$27.9MQ2 2025$33.0MQ3 2025$53.3MQ4 2025$50.0MQ1 2026$46.5MQ2 2026$47.4MQ3 2026
Operating cash flow less capital spending.
Kiniksa Pharmaceuticals International: operating cash flow against capital spendingKiniksa Pharmaceuticals International: operating cash flow against capital spendingOperating cash flowCapital spending$18.8M$193KQ4 2024$22.3M$99KQ1 2025$28.1M$165KQ2 2025$33.7M$671KQ3 2025$53.9M$633KQ4 2025$50.2M$161KQ1 2026$47.2M$663KQ2 2026$47.5M$180KQ3 2026
Latest (Q3 2026): Operating cash flow $47.5M, Capital spending $180K.

Capital allocation, year by year

Kiniksa Pharmaceuticals International: where the cash came from (up) and went (down), by fiscal yearKiniksa Pharmaceuticals International: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$126MFY2021: Shares issued $5.3MFY2021: Capital spending −$415K$5.3MFY2021FY2022: Operating cash flow $5.8MFY2022: Shares issued $2.6MFY2022: Asset sales $91KFY2022: Capital spending −$105K$8.5MFY2022FY2023: Operating cash flow $13.3MFY2023: Shares issued $2.9MFY2023: Capital spending −$130K$16.2MFY2023FY2024: Operating cash flow $25.7MFY2024: Shares issued $17.2MFY2024: Asset sales $25KFY2024: Capital spending −$277K$43.0MFY2024FY2025: Operating cash flow $138MFY2025: Shares issued $40.8MFY2025: Capital spending −$1.6M$179MFY2025
Over these 5 years operating cash flow totalled $56.5M; the largest uses were operating cash flow ($126M) and capital spending ($2.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$569M
Debtnone
Net cash$569M

Kiniksa Pharmaceuticals International funds itself: free cash flow was $197M over the last twelve months, with $569M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Kiniksa Pharmaceuticals International: sources (+) and uses (−) of cash, Q3 2026Kiniksa Pharmaceuticals International: sources (+) and uses (−) of cash, Q3 2026Other investing−$138MCash drawn (+) / kept (−)$94.0MOperating cash flow$47.5MTaxes on employees’ shares−$9.1MShares issued$6.1MCapital spending−$180K
Kiniksa Pharmaceuticals International: sources (+) and uses (−) of cash, TTM to Q3 2026Kiniksa Pharmaceuticals International: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$313MOperating cash flow$199MCash drawn (+) / kept (−)$93.2MShares issued$38.6MTaxes on employees’ shares−$15.8MCapital spending−$1.6M

From profit to cash

Kiniksa Pharmaceuticals International: net income to operating cash flow, Q3 2026Kiniksa Pharmaceuticals International: net income to operating cash flow, Q3 2026Net income$47.3MDepreciation & amortization$490KStock-based pay$13.1MDeferred taxes−$6.6MGains on disposals$8KReceivables−$7.3MInventory−$37.1MPayables−$8.2MAccrued liabilities$28.9MPrepaid and other assets$5.8MOther liabilities$11.5MOperating cash flow$47.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 2026929727278
Q2 2026927871216
Q1 2026827757228
Q4 20251521118209
Q3 20252120334190
Q2 20252117227166
Q1 20252712210139
Q4 20242514127140

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$47.5M−$180K$6.1M$94.0M$47.4M
Q2 2026$47.2M−$663K$17.6M$14.3M$46.5M
Q1 2026$50.2M−$161K$6.4M−$24.4M$50.0M
Q4 2025$53.9M−$633K$8.6M$9.3M$53.3M
Q3 2025$33.7M−$671K$16.3M$17.2M$33.0M
Q2 2025$28.1M−$165K$12.7M−$34.9M$27.9M
Q1 2025$22.3M−$99K$3.2M$26.4M$22.2M
Q4 2024$18.8M−$193K$2.7M−$86.2M$18.6M

Kiniksa Pharmaceuticals International: income statement and cash flow

Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%. The chart follows the revenue to costs, profit and cash.

Kiniksa Pharmaceuticals International: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.